Inflammatory cytokines and inflamed colon tissue

Inflammatory cytokines within inflamed colon tissue constitute a diverse group of signaling proteins that orchestrate the immune response in conditions like Inflammatory Bowel Disease (IBD) (Neurath, 2014, Nature Reviews Immunology). Key mediators include Tumor necrosis factor-alpha (TNF-alpha), Interleukin-12 (IL-12), Interleukin-23 (IL-23), and Interleukin-6 (IL-6), which are significantly upregulated in the colonic mucosa of patients with Crohn's disease and ulcerative colitis (Friedrich et al., 2019, JCI Insight). These cytokines promote the recruitment of immune cells, enhance the production of tissue-degrading proteases, and disrupt the intestinal epithelial barrier, leading to chronic ulceration and tissue damage (Salas et al., 2020, Nature Reviews Gastroenterology & Hepatology). Therapeutic intervention typically involves monoclonal antibodies that neutralize these cytokines or small molecules that inhibit their intracellular signaling pathways, such as Janus kinase (JAK) inhibitors (Billiet et al., 2014, Gut). By dampening this cytokine-driven inflammatory cascade, treatments aim to induce mucosal healing and achieve long-term clinical remission in patients with chronic intestinal inflammation (Walsh et al., 2016, American Journal of Gastroenterology). The interaction between these cytokines and the colonic microenvironment remains a primary focus for developing next-generation precision medicines and targeted delivery systems.

Other names

Pro-inflammatory cytokinesIBD-associated cytokinesColonic inflammatory mediatorsCytokine storm in colitisIntestinal inflammatory cytokines

Neutralization of pro-inflammatory cytokines (e.g., Tumor necrosis factor-alpha, Interleukin-12, Interleukin-23) via monoclonal antibodies or inhibition of downstream intracellular signaling (e.g., Janus kinase/STAT pathway) to reduce mucosal inflammation and promote tissue healing in the colon.